A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)

Background: The REFLECT phase-III trial has demonstrated the efficacy of lenvatinib in improving the overall survival of advanced hepatocellular carcinoma (HCC) patients, comparable to sorafenib. The rapidly evolving landscape of hepatocellular carcinoma therapy presents new avenues for lenvatinib....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cong-Cong, Yu, Cai-Yan, Zhang, Jing, Wang, Rui, Kong, Xiang-Shuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301759/
https://www.ncbi.nlm.nih.gov/pubmed/37388443
http://dx.doi.org/10.3389/fphar.2023.1159286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301759/
https://www.ncbi.nlm.nih.gov/pubmed/37388443
http://dx.doi.org/10.3389/fphar.2023.1159286

Ejemplares similares